Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 2 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Harbinger Health Inc. is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are concentrated among 2 distinct examiners, which suggests a high degree of familiarity between the company and the assigned officials. The portfolio is also focused within 2 distinct art units, indicating that the technical subject matter is specialized within the broader biotechnology field.
The busiest examiner for this portfolio is HASAN, KHALEDA B, who is responsible for 4 busiest examiner pending office actions. This means that 4 out of the 5 pending office actions are being reviewed by a single individual, giving HASAN, KHALEDA B significant influence over the company's current prosecution outcomes. The remaining action is handled by another of the 2 distinct examiners. With such a concentration of work under one examiner and within 2 distinct art units, practitioners can develop a very targeted strategy. Understanding the specific preferences of HASAN, KHALEDA B will be essential for managing the majority of the company's active applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| Double-patenting + other | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 4 | 59.3% | +49.0% |
| SMITH, EMILIE ALINE | 1 | 49.4% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19339016 | TIERED TESTING FOR HIGH RISK POPULATIONS | SMITH, EMILIE ALINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19339016 | TIERED TESTING FOR HIGH RISK POPULATIONS | SMITH, EMILIE ALINE | — |
| 18519589 | SOLID PHASE NEGATIVE ENRICHMENT | HASAN, KHALEDA B | — |
| 18385649 | BODILY FLUID TARGET ENRICHMENT | HASAN, KHALEDA B | — |
| 18131634 | SOLID PHASE NEGATIVE ENRICHMENT | HASAN, KHALEDA B | — |
| 18121328 | BODILY FLUID TARGET ENRICHMENT | HASAN, KHALEDA B | — |
| Art Unit | Apps |
|---|---|
| 1636 | 4 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19339016 | TIERED TESTING FOR HIGH RISK POPULATIONS | SMITH, EMILIE ALINE | 1686 | §101§112DP | Non-Final OA | — | Pending | Sep 24, 2025 |
| 18519589 | SOLID PHASE NEGATIVE ENRICHMENT | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18385649 | BODILY FLUID TARGET ENRICHMENT | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18131634 | SOLID PHASE NEGATIVE ENRICHMENT | HASAN, KHALEDA B | 1636 | §103DP | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18121328 | BODILY FLUID TARGET ENRICHMENT | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHarbinger Health Inc. has 5 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Khaleda B Hasan has the most, with 4 of Harbinger Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
